Blue Cross Blue Shield plans, CVS Health and UnitedHealth Group hold dozens of active investments in startups and emerging companies.

First, this Modern Healthcare article; "Why health insurers are shifting venture capital arm strategies" by Noah Tong. Fairly active.

Harvard Business School Accounting & Management Unit Working Paper No. 24-073

Exploring the "kingmaking" fallacy in venture capital; the notion that more capital can increase the odds of startup success.

Exposome analyses across 34 countries showed that social exposures were associated with faster functional brain aging and physical exposures with faster structural brain aging.

Why we need to shift our horizon, the most promising clinical trials, and how to enroll in them

A team of University of Kentucky researchers has uncovered a surprising clue in the battle against Alzheimer’s disease that could help doctors predict, and ultimately prevent, a common side effect of the newest generation of Alzheimer’s therapies. Their findings, recently published in Nature Communications, reveal a distinct immune “fingerprint” in the blood of patients who develop amyloid-related imaging abnormalities (ARIA) after treatment with lecanemab — the first FDA-approved drug shown to slow Alzheimer’s disease progression. The study was recognized as an Editors’ Highlight by Nature Communications, a designation the journal reserves for research its editors consider particularly noteworthy and impactful.